Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd is a large pharma headquartered in Switzerland. Over the past three years, Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd has been involved in 8 licensing and acquisition transactions, with a primary focus on Small Molecules (8 deals).
Deals (12mo)
6
Active Trials
0
Top Modality
Small Molecules
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| BTK degrader program | Roche | Small Molecules | Unknown | collaboration | Jun 9, 2026 |
| Poseida cell-therapy platform | Roche | Cell Therapy | Unknown | acquisition | May 24, 2026 |
| PathAI digital pathology and AI diagnostic platform | Roche | Other | Unknown |
Therapeutic areas and modalities where Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd is most active based on deal history and clinical trial data.
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd include Oncology (9 deals and trials), Other (2 deals and trials), Neurology (1 deal and trial), and Immunology (1 deal and trial). In terms of modality, Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd has shown particular interest in small molecules, cell therapy, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
| acquisition |
| May 17, 2026 |
| avapritinib | Roche | Small Molecules | Approved | co development | May 17, 2026 |
| protein degraders | Roche | Small Molecules | Unknown | collaboration | Apr 10, 2026 |
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals